Hainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial

Stock News

Jun 24

Hainanhaiyao Co.,Ltd. (SHE: 000566) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.

Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.

The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1106638512"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106638512\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106638512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106638512","market":"hk","top_or_hot":-1,"title":"Hainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial","media":"Stock News","content":"<p><b>Hainanhaiyao Co.,Ltd.</b> (<b>SHE: 000566</b>) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.<br><br>Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.<br><br>The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHainanhaiyao's Novel Anti-Hepatic Fibrosis Drug Completes Phase II Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-24 21:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Hainanhaiyao Co.,Ltd.</b> (<b>SHE: 000566</b>) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.<br><br>Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.<br><br>The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000566","symbol_name":"海南海药","start_time":0,"source_url":"","article_id":"1106638512","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106638512","pubTimestamp":1782306681,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hainanhaiyao Co.,Ltd. (SHE: 000566) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","000566":"海南海药","BK0146":"智慧医疗","BK0239":"医药制造","06978":"永泰生物-B","BK1161":"生物科技","BK0070":"员工持股","BK0188":"融资融券","BK1574":"生物医药B类股","BK0060":"抗癌"},"translate_title":"海南海药抗肝纤维化新药完成II期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"000566":1},"content_text":"Hainanhaiyao Co.,Ltd. (SHE: 000566) has announced the completion of a Phase II clinical trial for its innovative anti-hepatic fibrosis drug, Flufenidone Capsules, with the Phase III study now progressing as scheduled.Concurrently, the company's novel anti-epileptic drug, Paienjiabin Tablets, has concluded its Phase IIa trial, and the Phase IIb clinical trial is advancing according to plan.The company highlights that new drug development is characterized by long cycles, substantial investment, and high risks. The clinical trial process and outcomes involve numerous uncertainties, and there is no guarantee of subsequent regulatory approval for market launch. These developments are not expected to have a significant impact on the company's financial performance in the short term.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}